CC
CUE icon

Carlson Capital’s Cue Biopharma CUE Stock Holding History

Carlson Capital’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-667
Closed -$37.8K – 103
2024
Q1 		$37.8K Sell
667
-3,333
-83% -$235K ﹤0.01% 113
2023
Q4 		$317K Sell
4,000
-500
-11% -$35.7K 0.03% 117
2023
Q3 		$311K Buy
4,500
+32
+0.7% +$3.12K 0.02% 128
2023
Q2 		$489K Sell
4,468
-4,000
-47% -$470K 0.04% 110
2023
Q1 		$907K Sell
8,468
-3,699
-30% -$353K 0.09% 99
2022
Q4 		$1.04M Sell
12,167
-5,666
-32% -$518K 0.08% 104
2022
Q3 		$1.19M Sell
17,833
-1,500
-8% -$129K 0.09% 104
2022
Q2 		$1.44M Buy
19,333
+5,833
+43% +$682K 0.1% 108
2022
Q1 		$1.98M Buy
13,500
+7,167
+113% +$1.52M 0.14% 123
2021
Q4 		$2.15M Buy
6,333
+2,906
+85% +$1.12M 0.12% 114
2021
Q3 		$1.5M Sell
3,427
-1,596
-32% -$557K 0.08% 145
2021
Q2 		$1.76M Sell
5,023
-130
-3% -$50.4K 0.08% 133
2021
Q1 		$1.89M Buy
5,153
+2,320
+82% +$955K 0.07% 149
2020
Q4 		$1.06M Buy
+2,833
New +$1.13M 0.04% 145

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Carlson Capital's CUE Position: Q2 2024 in Review

Carlson Capital sold out of Cue Biopharma (CUE) in Q2 2024, closing a stake of 667 shares — an estimated $37.8K sold.

Carlson Capital first reported a position in CUE in Q4 2020 and held it in 14 quarters. The position peaked at $2.15M in Q4 2021. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2024.

  • Carlson Capital reported no remaining Cue Biopharma position as of Q2 2024 after selling out during the quarter.
  • Carlson Capital sold 667 Cue Biopharma shares in Q2 2024, an estimated $37.8K.
  • Carlson Capital first reported a position in Cue Biopharma in Q4 2020 and held it in 14 quarters.
  • Carlson Capital's Cue Biopharma position peaked at $2.15M in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2024.

Based on Carlson Capital's 13F filing for Q2 2024, filed 14 Aug 2024.